lomustine has been researched along with Dysmyelopoietic Syndromes in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma." | 5.07 | Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group. ( Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Risk of leukemia was 0." | 1.30 | The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawa, R | 1 |
| Palva, IP | 1 |
| Ala-Harja, K | 1 |
| Almqvist, A | 1 |
| Elonen, E | 1 |
| Hallman, H | 1 |
| Hänninen, A | 1 |
| Ilvonen, M | 1 |
| Isomaa, B | 1 |
| Jouppila, J | 1 |
| Järvenpää, E | 1 |
| Brusamolino, E | 1 |
| Anselmo, AP | 1 |
| Klersy, C | 1 |
| Santoro, M | 1 |
| Orlandi, E | 1 |
| Pagnucco, G | 1 |
| Lunghi, F | 1 |
| Maurizi-Enrici, R | 1 |
| Baroni, CD | 1 |
| Lazzarino, M | 1 |
| Mandelli, F | 1 |
| Bernasconi, C | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 1 |
1 review available for lomustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
1 trial available for lomustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leuke | 1993 |
2 other studies available for lomustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con
Topics: Abdomen; Actuarial Analysis; Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; | 1998 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |